Clostridioides difficile (CDI or C-diff, previously Clostridium difficile) is a spore producing, anoxic, gram-positive bacilli that has recently raised much concern in terms of public health around the globe. Our company provides one-stop services for CDI vaccine and therapy development.
Overview of Clostridioides Difficile Infection
The virulent factors of C. pesada is due to two extreme toxins which are TcdA and TcdB. These toxins badly damage the epithelial cells of the colon and as a result a very strong inflammatory response is followed which leads to the formation of pseudomembranes in the colon. The pathogenesis of developing C. difficile infection is further exacerbated by the perturbation of the gut flora, the change in the metabolism of bile acids and the response of the host towards the disease.
Fig. 1 Expression of Tcd169 in the nontoxigenic C. difficile CCUG37785 (designated NTCD). (Wang S., et al., 2022)
Vaccine Development for Clostridioides Difficile Infection
Formalin-inactivated Toxoid-based Vaccines
Advancing these vaccine candidates into clinical trials, the investigators have assessed their safety and immunogenicity in normal subjects. It is notable that all of the Phase 1 trials for toxoid vaccines show a high level of tolerance and the ability to generate robust serum antibody response above ninety percent. In addition, phase 2 trials evaluated the adjuvant at the optimal dose and maximum formulation to enhance the immune response, thus priming for clinical development at later stages.
Recombinant Fusion Protein Vaccines
At the same time, efforts to produce vaccines based on recombinant fusion proteins have been made. A next generation of vaccine candidates utilizes key epitopes of C. difficile toxin A and B fusion proteins to induce an immune response. The safety and immunogenicity of recombinant fusion protein vaccines have been shown in early-stage trials in healthy adults and older people.
Therapeutics Development for Clostridioides Difficile Infection
Antibiotic Therapies
Historically, metronidazole was the reference drug in this space before vancomycin and fidaxomicin emerged as first line therapies owing to their superior rates of cure and rates of recurrence respectively. Other antibiotics, namely Rifaximin, are also being assessed with the aim of lowering the rate of recurrence.
Non-Antibiotic Therapies
Fecal microbiota transplantation works on the principle of repopulating the gut microbiome and is most effective therapy for recurrent CDI, Bezlotoxumab is a monoclonal antibody against toxin B and reduces the risk of recurrent infection.
Our Services
Using our in-depth understanding of CDI pathogenesis , attention is given towards the engineering of vaccines and therapies which can both efficiently treat and prevent this infection. We work in a comprehensive fashion and incorporate new technologies with well-established methods to try to develop solutions which are effective and at the same time affordable for the people at the greatest risk.
Disease Models
- Hamster Models (C. difficile infection)
- Mouse Models (conventional, gnotobiotic, and human microbiota-associated mouse models)
- Rat Models (ileal loop models)
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
We participate in research efforts alongside scientists to further enhance and refine our vaccines and therapeutics. It is our aspiration that the guiding principles of this corporation assists the Big Pharma in crafting adaptive solutions. In case our activities were of your interest, please feel free to contact us for details or any further services you wish to discuss for tailoring a proposal to suit your needs, we will be glad to assist.
References
- Wang Shaohui, Duolong Zhu, and Xingmin Sun. "Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection." Microbiology spectrum 10.3 (2022): e00263-22.
- Guery Benoit, Tatiana Galperine, and Frédéric Barbut. "Clostridioides difficile: diagnosis and treatments." Bmj 366 (2019).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
